Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility

PLoS Genetics

Volumn 6, Issue 7, 2010, Pages 1-8

  Low, Yen Ling ^a   Li, Yuqing ^a   Humphreys, Keith ^b   Thalamuthu, Anbupalam ^a   Li, Yi ^a   Darabi, Hatef ^b   Wedrén, Sara ^b   Bonnard, Carine ^a   Czene, Kamila ^b   Iles, Mark M ^c   Heikkinen, Tuomas ^d   Aittomäki, Kristiina ^d   Blomqvist, Carl ^d,e   Nevanlinna, Heli ^d   Hall, Per ^b   Liu, Edison T ^a   Liu, Jianjun ^a  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; AROMATASE; ESTROGEN; ESTROGEN RECEPTOR; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B4; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN SYNTHESIS; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; ENDOMETRIUM CANCER; ESTROGEN METABOLISM; FEMALE; FINLAND; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAXIMUM LIKELIHOOD METHOD; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; ANALYSIS OF VARIANCE; BREAST TUMOR; CASE CONTROL STUDY; CAUCASIAN; COHORT ANALYSIS; ENDOMETRIUM TUMOR; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; TUMOR CELL LINE;

AGED; ANALYSIS OF VARIANCE; ANDROGENS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; ESTROGENS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN;

EID: 77957353800     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1001012     Document Type: Article

References (39)

1. Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ, et al. (2005) Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14: 357-366.
2. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, et al. (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59: 4870-4875.
3. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, et al. (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39: 352-358.
4. Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR (2005) Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 14: 1998-2003.
5. Tao MH, Cai Q, Zhang ZF, Xu WH, Kataoka N, et al. (2007) Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 16: 943-949.
6. Gaudet MM, Lacey JV, Jr., Lissowska J, Peplonska B, Brinton LA, et al. (2008) Genetic variation in CYP17 and endometrial cancer risk. Hum Genet 123: 155-162.
7. Thompson PA, Ambrosone C (2000) Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr. pp 125-134.
8. Berstein LM, Imyanitov EN, Kovalevskij AJ, Maximov SJ, Vasilyev DA, et al. (2004) CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett 207: 191-196.
9. Tyrer J, Pharoah PD, Easton DF (2006) The admixture maximum likelihood test: a novel experiment-wise test of association between disease and multiple SNPs. Genet Epidemiol 30: 636-643.
10. Dadd T, Weale ME, Lewis CM (2009) A critical evaluation of genomic control methods for genetic association studies. Genet Epidemiol 33: 290-298.
11. Bulun SE, Chen D, Lu M, Zhao H, Cheng Y, et al. (2007) Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol 106: 81-96.
12. Wang K, Li M, Bucan M (2007) Pathway-Based Approaches for Analysis of Genomewide Association Studies. Am J Hum Genet 81.
13. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3: e42. doi:10.1371/journal.pgen.0030042.
14. Lin NU, Winer EP (2008) Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26: 798-805.
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
16. Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94: 606-616.
17. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96: 1856-1865.
18. Ma H, Bernstein L, Pike MC, Ursin G (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a metaanalysis of epidemiological studies. Breast Cancer Res 8: R43.
19. Clavel-Chapelon F (2002) Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer 86: 723-727.
20. Shantakumar S, Terry MB, Teitelbaum SL, Britton JA, Millikan RC, et al. (2007) Reproductive factors and breast cancer risk among older women. Breast Cancer Res Treat 102: 365-374.
21. Hamilton AS, Mack TM (2003) Puberty and genetic susceptibility to breast cancer in a case-control study in twins. N Engl J Med 348: 2313-2322.
22. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, et al. (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91: 1131-1137.
23. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, et al. (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestinreplacement therapy. Int J Cancer 81: 339-344.
24. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, et al. (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92: 1529-1531.
25. Kilpivaara O, Bartkova J, Eerola H, Syrjakoski K, Vahteristo P, et al. (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113: 575-580.
26. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, et al. (2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40: 844-853.
27. Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H (2000) Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36: 1143-1148.
28. Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, et al. (1997) Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 6: 2309-2315.
29. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, et al. (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71: 432-438.
30. Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H (2001) A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84: 704-708.
31. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093.
32. Dunning AM, Healey CS, Baynes C, Maia AT, Scollen S, et al. (2009) Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 18: 1131-1139.
33. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, et al. (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 41: 585-590.
34. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F (1994) Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 145: 1301-1308.
35. Qin ZS, Niu T, Liu JS (2002) Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 71: 1242-1247.
36. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, et al. (2003) Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55: 27-36.
37. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229.
38. Weale ME, Depondt C, Macdonald SJ, Smith A, Lai PS, et al. (2003) Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping. Am J Hum Genet 73: 551-565.
39. Iles MM (2006) Obtaining unbiased estimates of tagging SNP performance. Ann Hum Genet 70: 254-261.